FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria di Stack

Immune Shield

Immune Supportbeginner

89

sintesi

89
Share
Peptidi

2

Media giornaliera mcg

1,750

Livello

beginner

Aggiunto

May 17, 2026

Panoramica

The Immune Shield stack combines the most clinically validated immune-enhancing peptide with a systemic repair compound to create a foundational immune optimization protocol. Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide that was originally isolated from thymic extract (Thymosin Fraction 5) by Allan Goldstein at George Washington University. It functions as the primary signal for T-cell maturation and activation — without adequate thymic output, the adaptive immune system cannot mount effective responses to novel pathogens or maintain immune surveillance against malignant cells. Ta1 is approved in 35+ countries (as Zadaxin) for hepatitis B, hepatitis C, and as a vaccine adjuvant, with over 4,400 published clinical papers documenting its efficacy and safety. BPC-157 is included for its unique influence on the gut-immune axis. Approximately 70% of immune tissue resides in the gut-associated lymphoid tissue (GALT), and intestinal barrier integrity directly influences systemic immune function. BPC-157''s documented effects on tight junction repair, mucosal healing, and modulation of the enteric nervous system support immune function at its largest interface with the external environment. Additionally, BPC-157''s anti-inflammatory properties help redirect immune resources from chronic low-grade inflammation toward active immune surveillance. The combination addresses immune health from two levels: Ta1 provides direct immune cell activation and maturation (top-down immune enhancement), while BPC-157 optimizes the mucosal barrier and gut immune environment that serves as the foundation of immune competence (bottom-up immune support). This stack is classified as beginner-friendly because both peptides have extensive safety data (Ta1 from international clinical use, BPC-157 from decades of animal research), the dosing schedule is simple, and there are no significant drug interactions or monitoring requirements. It is suitable for seasonal immune support, travel prophylaxis, or as a foundation for individuals with recurrent infections.

Protocollo di Dosaggio

Thymosin Alpha-1

2x/week· subcutaneous

Leggi di più su Thymosin Alpha-1 →

1,500 mcg

per dose

BPC-157

Every day· subcutaneous

Leggi di più su BPC-157 →

250 mcg

per dose

Obiettivi & Evidenze

Immune functionInfection resistanceGut-immune axisT-cell activationInflammation
Livello di Evidenza:RCT umano

Avvertenze

  • Thymosin Alpha-1 remains FDA Category 2 (restricted) in the US (approved abroad in 35+ countries as Zadaxin). BPC-157 was removed from FDA Category 2 (April 2026) but remains under PCAC review — not legal to compound yet. Good safety profile in clinical literature.

Comments

Sign in to join the discussion

Avvertenza: Questo stack è compilato dalla comunità e a scopo di ricerca solo. Peptide Contacts non verifica la sicurezza o l'efficacia dei stack compilati. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi protocollo di peptidi.